Acquired epidermodysplasia verruciformis in renal-transplant recipients

Soumaya Gara¹, meriem jones¹, Noureddine Litaiem¹, Hafedh Hedri¹, Soumaya Rammeh¹, and Faten Zeglaoui¹

¹Charles Nicolle Hospital

April 27, 2020

Abstract
Acquired epidermodysplasia verruciformis is a rare entity occurring in immunocompromised patients such as organ-transplant recipients. Renal-transplant recipients are at high risk for developing squamous cell carcinomas. The impact of acquired epidermodysplasia verruciformis on this risk is unknown. Long-term follow-up of this high-risk population should be proposed.

Title: Acquired epidermodysplasia verruciformis in renal-transplant recipients
Author names: Soumaya Gara¹, MD, Meriem Jones¹, MD, Noureddine Litaiem¹, MD, Hafedh Hedri², MD, Soumaya Rammeh³, MD, Faten Zeglaoui¹, MD
Author affiliations:
1. Department of dermatology, Charles Nicolle Hospital, Tunis, Tunisia
2. Department of nephrology, Charles Nicolle Hospital, Tunis, Tunisia
3. Department of pathology, Charles Nicolle Hospital, Tunis, Tunisia
Corresponding author:
Soumaya Gara
Department of dermatology, Charles Nicolle hospital,
9 April Street 1938, Bab Bnet, Tunis, 1006, Tunisia
Email address: soumayagara33@gmail.com
Conflict of interest: none to disclose
Funding: None
Keywords: dermatology, nephrology, oncology, health maintenance
Key Clinical message:
acquired epidermodysplasia verruciformis in renal-transplant recipients is associated with a high risk for developing squamous cell carcinoma. An accurate diagnosis and a regular monitoring in this high-risk population must be stressed.

Introduction:
Epidermodysplasia verruciformis (EV) is a rare autosomal recessive genodermatosis, associated with a high susceptibility to infection with particular genotypes of human papillomaviruses (HPV) that are innocuous
for the general population. Acquired forms of EV have been recently distinguished as an entity occurring in immunocompromised patients such as HIV-infected subjects or organ-transplant recipients. Clinical presentation can be variable, often similar to the inherited forms. Studies reporting acquired EV in renal-transplant recipients are scarce. Herein, we report a case of an acquired EV in a renal-transplant recipient and review the available literature data.

Case Report:

A 30-year-old male patient with a four-year history of kidney transplantation and a history of a drug reaction to amphotericin B he received for a visceral leishmaniasis, presented for a recurrence of the cutaneous eruption, evolving for the last 6 months. He was under post-transplant maintenance immunosuppressive therapy including prednisone, Mycophenolate mofetil and azathioprine. Physical examination revealed multiple erythematous and confluent macules and papules of the torso and abdomen (Fig. 1a,b,c). No verrucous lesions or tinea versicolor-like lesions were found. A skin biopsy of the macules was performed. Histological examination showed, in the upper epidermis, foci of keratinocytes of increased size, with enlarged nuclei and a bubbly, bluish, abundant cytoplasm, containing variably sized keratohyaline granules (Fig. 2). There were no signs of drug reaction. Histological features were consistent with the diagnosis of acquired EV. There was no history of affected relatives. A regular sunscreen application and close follow-up were proposed.

Discussion:

EV is a rare inherited genodermatosis characterized by an increased susceptibility to specific genotypes of human papillomaviruses (HPV). HPV 5 and 8 are reported to be the major causative agents. Causal genetic mutations have been identified in the EVER genes. The etiopathogenesis is multifactorial, involving viral, genetic and environmental factors. Over time, affected subjects have an increased risk of squamous cell carcinoma on sun-exposed areas. In 1983, Lutzner and colleagues had detected, in a renal-allograft recipient, HPV 5 DNA, in both Squamous cell carcinomas and benign skin lesions that resemble clinically and histologically to the lesions of inherited EV. They suggested a synergistic action between HPV infection, immunosuppression and sunlight exposure in the occurrence of skin carcinoma in renal-transplant recipient. Acquired EV is a term coined in 2009 by Rogers and colleagues to describe acquired phenotypes of EV discovered in HIV patients. Other conditions of suppressed cellular immunity have been associated with acquired EV such as systemic lupus erythematosus, GVH disease, atopic dermatitis and solid organ transplantation such as renal transplantation. The description of acquired EV in immunocompromised hosts suggests the potential role of a specific immune deficiency. A novel classification for the different types of EV subdivides the disease into genetic EV (classic and non-classic according to the mutations) and acquired EV. Although an underlying genetic susceptibility to HPV infection in immunocompromised patients with acquired EV has been hypothesized, it has not yet been identified.

Clinically, acquired EV manifests usually with the same features as genetic EV, namely a tinea versicolor-like eruption of the trunk, face and extremities and verruca-like lesions on the distal extremities. Published data about acquired EV related to renal transplantation is scarce with mainly single case reports. Table 1 shows all reported clinical cases of acquired EV in renal-transplant recipients. Most cases have a typical presentation. In other papers, the presentation was atypical with lesions limited to the perineum and the inguinal folds. A case of acquired EV mimicking a periangual malignant melanoma was reported in a patient diagnosed with a cutaneous T cell lymphoma. In our case, the diagnosis was discovered fortuitously on a biopsy for a drug reaction suspicion.

As for cancer susceptibility, the progression to non-melanoma skin cancers in acquired EV has not been well established. In organ-transplant recipients, the use of immunosuppressive medications to prevent organ rejection is responsible for increasing the susceptibility for viral infections, particularly HPV, that may explain the occurrence of the acquired EV phenotypes. In his report, Mendes highlights the role of post-transplantation immunosuppressive medications in increasing both the susceptibility for viral infections and the rate of malignancies. This effect is caused by most of the molecules used. In the cases of the literature, all renal-transplant recipients were undergoing maintenance immunosuppressive therapy.
suppressant molecules are known to increase the risk of malignancy. Similarly to genetic EV, acquired EV may be associated with a higher rate of cutaneous cancers. The cumulative effect of these two risks in renal-transplant recipients is still unknown and an intensification of the monitoring could be an option. As a precaution, photoprotection is mandatory.

No effective curative treatment has yet been discovered for neither the genetic nor the acquired forms. Several treatment options have been proposed. However, no modality has been shown to be consistently successful. A case of an acquired EV in a renal-transplant recipient that cleared with a multimodal therapy including Gardasil vaccination has been reported.

Conclusion:
Acquired EV is a recent and rare entity, occurring in conditions with compromised cell-mediated immunity such as renal transplantation. The number of renal-transplant recipients has significantly increased in recent years which may lead to an increase in the prevalence of acquired EV. Transplant recipients are at high risk of developing non-melanoma skin cancers. It is important to recognize and accurately diagnose acquired EV because its impact on the cancer risk and its consequences on patient monitoring is still unknown. Cohort studies are required with long-term follow-up and continued evaluation to assess the relative risk for secondary skin cancers. The importance of regular sunscreen application must be stressed. Physicians should play a key role for the long-term dermatologic surveillance of this high-risk population.

<table>
<thead>
<tr>
<th>case reference</th>
<th>sex</th>
<th>age (years)</th>
<th>Underlying disease</th>
<th>medications</th>
<th>Clinical aspects</th>
<th>location</th>
<th>HPV type</th>
<th>histology</th>
<th>treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 [Our case]</td>
<td>M</td>
<td>30</td>
<td>Glomerulonephritis</td>
<td>MMF, predni-</td>
<td>Erythematous Torso,</td>
<td>-</td>
<td>In the epidermis, keratinocytes of increased size, with enlarged nuclei and a bubbly, bluish, cytoplasm that contains kerato-hyaline granules</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Case reference</td>
<td>Sex</td>
<td>Age (years)</td>
<td>Underlying disease</td>
<td>Medications</td>
<td>Clinical aspects</td>
<td>Location</td>
<td>HPV type</td>
<td>Histology</td>
<td>Treatment</td>
</tr>
<tr>
<td>----------------</td>
<td>-----</td>
<td>-------------</td>
<td>-------------------</td>
<td>-------------</td>
<td>-----------------</td>
<td>----------</td>
<td>----------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>2 [9]</td>
<td>M</td>
<td>24</td>
<td>Systemic lupus erythematosus With lupus nephritis</td>
<td>MMF, Prednisone, sirolimus</td>
<td>Erythematous face, neck, V-shaped neckline, forearms, abdomen</td>
<td>-</td>
<td>Vacuolated cells in the upper epidermis, bubbly bluish cytoplasm, thickened granular layer, perivascular infiltrate in the superficial dermis</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3 [14]</td>
<td>F</td>
<td>50</td>
<td>Alport syndrome</td>
<td>Tacrolimus, MMF, Prednisolone</td>
<td>Erythematous inguinal folds extending to the upper thighs</td>
<td>5</td>
<td>Enlarged keratinocytes with a blue-grey cytoplasm, vacuolated cells in the upper epidermis and coarse keratohyaline granules</td>
<td>Topical tretinoine 0.05% + topical imiquimod 5% + acitretin 10mg daily + three Gardasil vaccinations</td>
<td>-</td>
</tr>
<tr>
<td>4 [11]</td>
<td>F</td>
<td>44</td>
<td>Systemic lupus erythematosus</td>
<td>Cyclosporine, several grouped pink lichenoid macules</td>
<td>Upper mid chest, anterior neck, left leg</td>
<td>-</td>
<td>Viral epidermal cytopathic changes, blue cytoplasm, coarse hypergranulosis</td>
<td>Cryosurgery, Tazaroten cream 0.05%, imiquimod cream 5%, 5-fluorouracil cream 5%</td>
<td>-</td>
</tr>
<tr>
<td>Case</td>
<td>Reference</td>
<td>Sex</td>
<td>Age (years)</td>
<td>Underlying Disease</td>
<td>Medications</td>
<td>Clinical Aspects</td>
<td>Location</td>
<td>HPV Type</td>
<td>Histology</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----</td>
<td>-------------</td>
<td>--------------------</td>
<td>-------------</td>
<td>-----------------</td>
<td>----------</td>
<td>----------</td>
<td>-----------</td>
</tr>
<tr>
<td>5</td>
<td>[13]</td>
<td>F</td>
<td>66</td>
<td>Hypertension</td>
<td>Prednisone</td>
<td>Multiple papules coalescing into plaque</td>
<td>Perineum and perianal skin</td>
<td>5</td>
<td>Superficial keratinocytes with light gray cytoplasm surrounding slightly hyperchromatic and irregular nuclei</td>
</tr>
<tr>
<td>6</td>
<td>[12]</td>
<td>F</td>
<td>19</td>
<td>Glomerulonephritis</td>
<td>MMF, Tacrolimus, Prednisone</td>
<td>Erythematous papules</td>
<td>Upper limbs</td>
<td>23</td>
<td>Keratinocytes with vacuolated cytoplasm</td>
</tr>
<tr>
<td>7</td>
<td>[4]</td>
<td>M</td>
<td>35</td>
<td>Glomerulonephritis</td>
<td>Azathioprine, Prednisone</td>
<td>Macular, Scaly lesions</td>
<td>Arms, trunk</td>
<td>5</td>
<td>Keratinocytes with light gray cytoplasm surrounding slightly hyperchromatic and irregular nuclei</td>
</tr>
</tbody>
</table>

Table 1: characteristics of cases of acquired epidermodysplasia verruciformis in renal-transplant recipients.

: mycophenolate mofetil

**Author contribution statement:** Soumaya Gara, Meriem Jones, Noureddine Litaiem, Hafedh Hedri, Soumaya Ramme and Faten Zeglaoui participated in the management of this patient as well as in the preparation and edition of the manuscript. All authors read and approved the final manuscript.

**References:**

1. Limmer AL, Wu JH, Doan HQ, Rady PL, Tyring SK. Acquired epidermodysplasia verruciformis: a


Figures legend:

Fig. 1a,b,c: erythematous papules of the trunk

Fig. 2: Skin biopsy specimen (hematoxylin-eosin stain; original magnification: x40): in the upper epidermis, large keratinocytes with enlarged nuclei, a bubbly bluish cytoplasm and variably-sized keratohyaline granules